Among directors cited as principals in the filing with the US Securities and Exchange Commission, are John Reher and Karoly Nikolich of California-based Brain Trust Accelerator Fund, which was the sole investor in its A round in 2010.
The company says it is an early stage, product based, specialty pharmaceutical company located in Washington DC, focuses on the identification and initial clinical development of better medications for the treatment of neurologic and psychiatric disease.
Chase PHarmaceuticals was founded in 2007.
Chase Pharmaceuticals’ lead drug is CPC-001. a treatment for patients with Alzheimer’s disease and other dementias of the Alzheimer type, scheduled to enter Phase I studies in healthy volunteers in the first quarter of 2011 and begin Phase II proof of principle trials in the target patient population by the first quarter of 2012.
In addition, the company says on its Web site that it maintains an interest in the acquisition and clinical development of early- to mid-stage product candidates of exceptional promise. Included are those for the treatment of Parkinson’s disease, depression and stroke as well as other therapeutically underserved disorders of the central nervous system.
No comments:
Post a Comment